Skip Navigation

Clinical Trials in Public Health Emergencies: the Ebola and COVID Experiences

Loading video...

1,803 Views

Air date: Wednesday, May 13, 2020, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 1,803 (1,209 Live, 594 On-demand)
Category: COVID-19
Runtime: 00:57:48
Description: NIH COVID-19 SIG Lecture Series

Designing and implementing clinical trials for novel infectious disease treatments brings many challenges, especially during a rapidly evolving pandemic. A new disease brings uncertainties arising from an imperfect understanding about illness, limited information about proposed countermeasures, and complexities in measuring relevant patient outcomes. A pandemic adds an overloaded medical system with limited resources for research, heightened pressure to find cures quickly, and unpredictability about potential case numbers. I will discuss issues related to designing and conducting treatment trials in outbreaks of Ebola and COVID based on my experience with three studies: Prevail II (the West African Ebola virus disease study of ZMapp), PALM (the Democratic Republic of the Congo Ebola virus disease study of ZMapp, mAb114, REGN-EB3 and remdesivir) and ACTT-1 (the multinational, platform COVID-19 study of remdesivir vs placebo).
NLM Title: Clinical trials in public health emergencies : the Ebola and COVID experiences / Lori Dodd.
Author: Dodd, Lori.
National Institutes of Health (U.S.). COVID-19 Scientific Interest Group,
Publisher:
Abstract: (CIT): Designing and implementing clinical trials for novel infectious disease treatments brings many challenges, especially during a rapidly evolving pandemic. A new disease brings uncertainties arising from an imperfect understanding about illness, limited information about proposed countermeasures, and complexities in measuring relevant patient outcomes. A pandemic adds an overloaded medical system with limited resources for research, heightened pressure to find cures quickly, and unpredictability about potential case numbers. I will discuss issues related to designing and conducting treatment trials in outbreaks of Ebola and COVID based on my experience with three studies: Prevail II (the West African Ebola virus disease study of ZMapp), PALM (the Democratic Republic of the Congo Ebola virus disease study of ZMapp, mAb114, REGN-EB3 and remdesivir) and ACTT-1 (the multinational, platform COVID-19 study of remdesivir vs placebo).
Subjects: Coronavirus Infections--drug therapy
Emergencies
Hemorrhagic Fever, Ebola--drug therapy
Pandemics
Randomized Controlled Trials as Topic--methods
Severe Acute Respiratory Syndrome--drug therapy
Publication Types: Lecture
Webcast
 
NLM Classification: QV 771.4
NLM ID: 101769613
CIT Live ID: 37493
Permanent link: https://videocast.nih.gov/watch=37493

Related Videos...

Click Here to Play Video.
08:22:11
Emotional and Behavioral Health in Persons with Mental Retardation and Developmental Disabilities (Day 1)
[Conferences]
11/29/2001
Click Here to Play Video.
08:23:11
Bringing Therapeutic Cancer Vaccines and Immunotherapies Through Development to Licensure (Day 1)
[Conferences]
2/8/2007
Click Here to Play Video.
06:28:24
Cancer and Inflammation - Day 1
[HHS Only]
10/9/2007
Click Here to Play Video.
07:58:21
Recombinant DNA Advisory Committee (RAC) September 2007 - Day 1
[Recombinant DNA Advisory Committee]
9/17/2007
Click Here to Play Video.
07:43:25
National Cancer Advisory Board - November 2007
[National Cancer Advisory Board]
11/27/2007
Click Here to Play Video.
07:20:27
FDA NIH WHO Public Workshop - Pandemic Vaccine Development (Day 2)
[Conferences]
12/11/2007
Click Here to Play Video.
04:08:20
NIH Blue Ribbon Panel Meeting - March 2008
[Advisory Boards and Councils]
3/13/2008
Click Here to Play Video.
07:24:21
Maximizing NIH's Levers to Catalyze Technology Transfer
[Conferences]
7/31/2023
Click Here to Play Video.
06:47:00
Annual Sickle Cell Disease Research FY23 (Day 3)
[Conferences]
8/16/2023
Click Here to Play Video.
08:29:00
17th Annual Sickle Cell in Focus - Day 2
[Special]
9/20/2024